Aptus Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →See revenue, profit and what management said. You are viewing Q4 FY26.
AP

Aptus Pharma Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Aptus Pharma Q4 FY26: Revenue ₹40.36 Cr, PAT ₹21.31 Cr

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Based on Aptus Pharma Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹347
Market cap₹606 Cr
P/E131.2

The short version

The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. EBITDA for the quarter: ₹36.11 crore, up 53.60% year-on-year - Operating margin: 20.2%, increased from 14.8% year-on-year - Profit after tax (PAT): ₹21.31 crore, up 42.82% year-on-year - Margin outlook: The presentation states the company is targeting sustained operating margins around 20%-22% going forward.

From Aptus Pharma Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026.
  • This represents a year-on-year revenue growth of 16% compared to ₹34.80 crore in Q4 FY2025.
  • Sales volume grew by 14% year-on-year during the quarter.

2 more points from Aptus Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aptus Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation mentions the following regarding capex, capacity expansion, and new projects: - **Capex Plan:** - Aptus Pharma is investing in capacity enhancement and new facility development. - Planned capital expenditure is approximately ₹15-20 crore. - **Capacity Expansion:** - Expansion primarily in the formulations segment to meet growing demand. - Enhancement includes increasing tablet compression and capsule-filling capacities. - **New Plant/Project:** - A new manufacturing plant is being set up in Gujarat. - The plant will manufacture both formulations and contract manufacturing products. - The project status is “under implementation.”

2 more points from Aptus Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aptus Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Aptus Pharma Ltd said on order book & pipeline — free account, 30 seconds.

What Aptus Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Morepen Laboratories (Q4 FY26)

    472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aptus Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aptus Pharma Ltd Q4 FY26 results?

The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. EBITDA for the quarter: ₹36.11 crore, up 53.60% year-on-year - Operating margin: 20.2%, increased from 14.8% year-on-year - Profit after tax (PAT): ₹21.31 crore, up 42.82% year-on-year - Margin outlook: The presentation states the company is targeting sustained operating margins around 20%-22% going forward.

What is Aptus Pharma Ltd share price analysis?

Aptus Pharma Ltd currently shows a neutral. The stock trades at a P/E of 131.2 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aptus Pharma Ltd planning capital expenditure?

The investor presentation mentions the following regarding capex, capacity expansion, and new projects: - Capex Plan: - Aptus Pharma is investing in capacity enhancement and new facility development.

Keep Aptus Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.